glp 1 agonist shortage Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Shortage: Deterioration of Glycemic Control in Type 2 Diabetes New alert for GLP-1 agonist
Description
We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth
For patients primarily seeking weight management, either with or without type 2 diabetes, higher-dose formulations such as semaglutide 2.4 mg (Wegovy) or liraglutide 3 mg (Saxenda) may be more appropriate
[DOI] [PubMed] [Google Scholar] 28.Ahrn B, Leguizamo Dimas A, Miossec P, et al
1 Previously, multiple other GLP-1 agonists reached the public (Table 1)
Regarding the secondary endpoint hospitalization due to heart failure, the results of the studies are heterogenous
